BioCentury
ARTICLE | Finance

Safety goes (Re)Viral

Strong safety data prompted Novo to co-lead ReViral’s $55M series B

August 1, 2018 9:28 PM UTC

The clean safety profile and clinical efficacy of ReViral Ltd.’s respiratory syncytial virus therapy prompted Novo Ventures to co-lead the biotech’s $55 million series B round with fellow new investor New Leaf Venture Partners.

The round closed Wednesday and saw participation from new investor Perceptive Advisors and existing investors Andera Partners, OrbiMed and Brace Pharma Capital...

BCIQ Company Profiles

Novo Ventures

ReViral Ltd.

BCIQ Target Profiles

RSV F protein